Annual Financial Report and Notice of AGM

TheraCryf plc

("TheraCryf", the "Company" or the "Group")

Posting of Annual Report and Notice of AGM

Alderley Park, UK - 21 June 2024: TheraCryf plc (AIM: TCF), the clinical stage drug development company focussing on oncology and neuropsychiatry, announces that its Annual Report and Accounts for the year ended 31 March 2024 have been posted to shareholders and are now available on the Company website.

Additionally, the Company's AGM will take place on at 2.30 p.m. on Thursday 18 July 2024 in the Block 11 Lecture Theatre, Alderley Park Conference Centre, Cheshire, United Kingdom, SK10 4TG.

-Ends-

Enquiries

About TheraCryf plc

TheraCryf is the clinical stage drug development company focussing on oncology and neuropsychiatry. The Company has a broad clinical and preclinical pipeline in indications including glioblastoma* neurodevelopmental disorders, addiction, anxiety and narcolepsy* [*orphan indications].

Its strategy is to generate compelling data sets to preclinical and/or clinical proof of concept and partner its clinical programmes with mid-size to large pharma for larger trials and commercialisation. As well as a number of industry partnerships with companies, including Stalicla SA, in neurodevelopmental disorders. The Company has sourced know how for programmes from companies such as Shire (now Takeda).

TheraCryf has worked with and has ongoing collaborations with major universities and hospitals such as the University of Manchester, La Sapienza (Università di Roma), the Erasmus Medical Centre, Rotterdam, Kings College London and University of Connecticut.

The Company has its headquarters and registered office at Alderley Park, Cheshire. It is listed on AIM in London and trades under the ticker symbol TCF. 

For further information, please visit: www.theracryf.com